Key Points
- Bioventus director Michelle Mcmurry-Heath sold 17,701 shares on Nov. 7 at an average price of $7.42 for $131,341.42, cutting her stake by 23.7% to 56,997 shares; the transaction was disclosed in an SEC filing.
- Shares opened at $7.49 with a market cap of $619.27 million, a negative P/E of -12.28, 50‑day/200‑day SMAs near $6.95/$6.87, and a 12‑month trading range of $5.81–$12.61.
- Institutional investors own about 62.94% of the company, with Vanguard (2.55M shares), Royce & Associates and others recently increasing their holdings.
Bioventus Inc. (NYSE:BVS - Get Free Report) Director Michelle Mcmurry-Heath sold 17,701 shares of the stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $7.42, for a total value of $131,341.42. Following the sale, the director owned 56,997 shares in the company, valued at $422,917.74. The trade was a 23.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Bioventus Trading Up 0.5%
NYSE:BVS opened at $7.49 on Tuesday. The firm has a market capitalization of $619.27 million, a P/E ratio of -12.28 and a beta of 0.80. The business has a 50 day simple moving average of $6.95 and a 200 day simple moving average of $6.87. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. Bioventus Inc. has a 12-month low of $5.81 and a 12-month high of $12.61.
Hedge Funds Weigh In On Bioventus
Several institutional investors have recently modified their holdings of BVS. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Bioventus during the first quarter worth about $143,000. Royce & Associates LP boosted its stake in Bioventus by 21.8% during the 1st quarter. Royce & Associates LP now owns 892,216 shares of the company's stock valued at $8,164,000 after purchasing an additional 159,980 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Bioventus by 35.6% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,181 shares of the company's stock worth $157,000 after purchasing an additional 4,513 shares during the last quarter. Mackenzie Financial Corp increased its stake in shares of Bioventus by 27.3% in the first quarter. Mackenzie Financial Corp now owns 41,090 shares of the company's stock valued at $376,000 after purchasing an additional 8,824 shares during the period. Finally, Vanguard Group Inc. raised its holdings in shares of Bioventus by 3.7% during the first quarter. Vanguard Group Inc. now owns 2,554,224 shares of the company's stock valued at $23,371,000 after buying an additional 92,143 shares during the last quarter. Institutional investors own 62.94% of the company's stock.
Bioventus Company Profile
(
Get Free Report)
Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
